-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Understanding the evolution of molecular changes in neurodegenerative diseases, such as Alzheimer's disease (AD), is essential for identifying and validating potential biomarkers for diagnosis , prognosis, or treatment
.
In addition to the signs of AD, amyloid and tau pathology, some early changes related to AD have been confirmed, such as low metabolism and structural changes in the brain
diagnosis
In addition, a lot of effort has been used to determine early changes in the cerebrospinal fluid (CSF) proteome to complement the measurement of amyloid β (Aβ42), total tau (t-tau), and phosphate tau (p-tau)
.
For example, the neurofilament light chain (NfL) has been considered a marker of neurodegeneration and may be used to track the progression of AD
However, in addition to AD, NfL is also increased in CSF in many neurodegenerative diseases, such as frontotemporal dementia, Parkinson's disease, and amyotrophic lateral sclerosis
.
Neurogranin (NRGN) and neuromodulin (GAP43) are two synaptic proteins that are also reportedly closely related to AD, but they seem to be more disease-specific than NfL
But compared with NfL, they seem to be more disease-specific
In the elderly population with normal and impaired cognitive ability, changes in the levels of 22 proteins in individuals with AD biomarker characteristics were found, which were defined by the levels of Aβ42, tau and p-tau in CSF
.
Of the 790 quantified proteins, 59 are related to the CSF pathology of Aβ42, t-tau or p-tau
In this way, Julia Remnestål of the Royal Institute of Technology in Sweden and others explored the association of 104 proteins, which are known to be enriched in the brain or related to different types of neurodegenerative diseases, and are related to the AD pathological evidence of CSF biomarkers.
They used technology based on multiple antibodies and magnetic beads to explore the levels of 104 proteins in the cerebrospinal fluid (CSF) of 307 asymptomatic 70-year-olds in the H70 Gothenburg Birth Cohort
.
They found that protein levels were first correlated with the core AD CSF biomarker concentrations of total tau, phospho-tau, and amyloid β (Aβ42) in all individuals
.
63 proteins showed significant correlation with total tau, tau phosphate or Aβ42
.
Individuals are divided according to the CSF Aβ42/Aβ40 ratio and the clinical dementia score (CDR) to determine whether the early changes in pathology and cognition have an impact on the relationship
.
They also compared the associations between the analyzed proteins and CSF markers between the groups, and found that 33 proteins showed significantly different associations in amyloid-positive individuals and amyloid-negative individuals, which is caused by CSF Aβ42/Aβ40 The ratio is determined
.
Individuals divided by CDR score did not differ in association
The important significance of this research lies in the discovery of a series of transmembrane proteins (proteins related to the plasma membrane, anchored on the plasma membrane, and involved in synaptic vesicle transport), which are related to CSF markers such as amyloid and tau in AD
.
.
Original source:
Remnestål J, Bergström S, Olofsson J, et al.
Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds.
Alz Res Therapy.
2021;13(1):54.
doi:10.
1186/ s13195-021-00789-5
Association of CSF proteins with tau and amyloid β levels in asymptomatic 70-year-olds.
Alz Res Therapy.
Leave a message here
